Allon Granted Key Japanese Patent for Davunetide
News Feb 14, 2011
Allon Therapeutics Inc. has announced that an important Japanese patent has been issued covering the composition of matter of the company's lead product davunetide and other peptides in its neuroprotection drug platform.
Davunetide is now being evaluated in a pivotal Phase 2/3 clinical trial as a potential treatment for progressive supranuclear palsy (PSP), a rapidly progressing and fatal degenerative brain disease which is often misdiagnosed as Parkinson's or Alzheimer's disease.
Alistair Stewart, Allon's Vice President of Commercial Research, said the Japanese patent expands the commercial market potential of davunetide beyond North America and Europe.
"Japan is the third largest pharmaceutical market and this patent means that we now have consistent core protection for davunetide in all the three major markets of the world for several brain degenerative diseases, including Alzheimer's disease, Parkinson's disease, and PSP," Stewart said.
"This is important because davunetide's clinical development has reached the stage where its commercialization is on the horizon and the patent portfolio becomes critical to our efforts in attracting pharma companies that might become our commercialization partners abroad."
The patent granted by the Japan Patent Office covers the polypeptide and nucleotide composition of matter for davunetide, its parent protein ADNP and other derivatives of ADNP.
Allon also reported that it has been granted a patent in the United States covering the treatment of fetal alcohol syndrome developed as a result of in-utero exposure to alcohol with davunetide or derivatives and combinations of all other compounds in the company's neuroprotection drug platform.
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE